# US 2025/0144140 A1 · Methods for allogeneic hematopoietic stem cell transplantation

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0144140 A1
- Document ID: US20250144140A1
- Status: Published application
- Kind: A1
- Application number: 18/916,371
- Filed: 2024-10-15
- Published: 2025-05-08
- Earliest claimed: 2022-04-15
- Assignees: Orca Biosystems, Inc.
- Applicants: Orca Biosystems, Inc.
- Inventors: Scott Killian; Scott McClellan; Amy Putnam; Nathaniel Fernhoff
- Web page: https://patentgrep.com/patent/US20250144140A1

## CPC

- A61K 35/17: Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes (when activated by a specific antigen A61K39/00)
- A61K 31/436: the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
- A61K 35/28: Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/421: {Immunoglobulin superfamily}
- A61K 40/4214: {Receptors for cytokines}
- A61P 35/02: specific for leukemia
- C07K 14/7051: {T-cell receptor (TcR)-CD3 complex}
- C07K 14/70514: {CD4}
- C07K 14/70589: {CD45}
- C07K 14/715: for cytokines; for lymphokines; for interferons
- A61K 2239/38: characterised by the dose, timing or administration schedule
- A61K 2239/48: Blood cells, e.g. leukemia or lymphoma
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Various embodiments of the present disclosure provide therapeutic compositions and associated methods for improved hematopoietic stem cell transplantations, including methods to enhance protection from graft versus host disease while maintaining effective immune responses such as graft versus tumor immune responses.

## Claims

### Claim 1

A multi-component cellular therapy product comprising:
a) a first single dose transfer bag comprising a first population of isolated CD45+ cells comprising a dose of approximately 1.0×105 to approximately 1.0×108 CD34+ hematopoietic stem and progenitor cells (HSPCs) per kilogram of body weight of a human subject receiving the product, wherein the first population of CD45+ cells is formulated with an excipient at a neutral pH;
b) a second single dose transfer bag comprising a second population of isolated CD45+ cells comprising a dose of approximately 1.0×105 to approximately 2.0×107 fresh CD4+CD25+CD127dim regulatory T cells (Tregs) per kilogram of body weight of the human subject receiving the product, wherein the second population of isolated CD45+ cells is formulated with an excipient at a neutral pH, optionally wherein the first single dose transfer bag and the second single dose transfer bag are the same transfer bag; and
c) a third single dose transfer bag comprising a third population of isolated CD45+ cells comprising a dose of approximately 1.0×105 to approximately 4.0×107 conventional CD3+ T cells (Tcons) per kilogram of body weight of the human subject receiving the product, wherein the third population of isolated CD45+ cells is formulated with an excipient at a neutral pH, wherein the excipient comprises one more cryoprotectants.

### Claim 2

(canceled)

### Claim 3 (depends on 1)

The multi-component cellular therapy product of claim 1, wherein the product further comprises a pharmaceutical composition comprising a dose of tacrolimus sufficient to maintain a trough blood level of approximately 5 ng/ml to approximately 10 ng/ml in the human subject receiving the product.

### Claim 4 (depends on 1)

The multi-component cellular therapy product of claim 1, wherein:
the first population of isolated CD45+ cells, the second population of isolated CD45+ cells, and/or the third population of isolated CD45+ cells is formulated at a volume that ranges from approximately 5 mL to approximately 1 L.

### Claim 5 (depends on 1)

The multi-component cellular therapy product of claim 1, wherein the first population of isolated CD45+ cells, the second population of isolated CD45+ cells, and the third population of isolated CD45+ cells are from an allogeneic donor having at least one HLA mismatch relative to the human subject receiving the product.

### Claim 6 (depends on 1)

A method of treating a human subject having or suspected of having a hematologic malignancy, the method comprising administering to the human subject the multi-component cellular therapy product of claim 1.

### Claim 7

A method of preparing a multi-component cellular therapy product comprising:
a) obtaining an HSPC-mobilized peripheral blood apheresis sample from a donor that is allogeneic with respect to a human subject receiving the product; and
b) selecting from the apheresis sample a first sample comprising from approximately 1.0×105 to approximately 1.0×108 CD34+ hematopoietic stem and progenitor cells (HSPCs) per kilogram of body weight of the human subject receiving the product, a second sample comprising from approximately 1.0×105 to approximately 2.0×107 CD4+CD25+CD127dim regulatory T cells (Tregs) per kilogram of body weight of the human subject receiving the product, and a third sample comprising from approximately 1.0×105 to approximately 4.0×107 conventional CD3+ T cells (Tcons) per kilogram of body weight of the human subject receiving the product, wherein the multi-component cellular therapy product comprises the Tcons, the HSPCs, and the Tregs, wherein the HSPCs are selected by sorting the first sample with one or more ISPs specific for CD34 and selecting a CD34-enriched population, wherein the Tregs are selected by soring the second sample with one or more ISPs specific for CD25, one or more ISPs specific for CD4, and/or one or more ISPs specific for CD127, and selecting the CD4+ and CD127dim cell population.

### Claim 8 (depends on 7)

A multi-component cellular therapy product produced by the method of claim 7.

### Claim 9 (depends on 1)

A method of treating a human subject having or suspected of having acute leukemia in complete remission, active leukemia, primary refractory acute leukemia, or acute leukemia with minimal residual disease, wherein the method comprises administering to the human subject the multi-component cellular therapy product of claim 1.

### Claim 10 (depends on 1)

A method of treating a human subject having or suspected of having low-risk acute myeloid leukemia (AML), high-risk AML in complete remission, or chronic myelogenous leukemia (CML), wherein the method comprises administering to the human subject the multi-component cellular therapy product of claim 1.

### Claim 11 (depends on 1)

A method of treating a human subject having or suspected of having high-risk myelodysplastic syndrome, therapy-related myelodysplastic syndrome, and/or secondary myelodysplastic syndrome, wherein the method comprises administering to the human subject the multi-component cellular therapy product of claim 1.

### Claim 12 (depends on 1)

A method of treating a human subject having or suspected of having a myeloproliferative syndrome, the method comprising administering to the human subject the multi-component cellular therapy product of claim 1.

### Claim 13 (depends on 1)

A method of treating a human subject having or suspected of having non-Hodgkin lymphoma with poor risk features not suitable for autologous hematopoietic cell transplant (HCT), the method comprising administering to the human subject the multi-component cellular therapy product of claim 1.

### Claim 14 (depends on 6)

The method of claim 6, wherein the third population of isolated CD45+ cells is administered from approximately 24 to approximately 120 hours after administration of the first population of isolated CD45+ cells and the second population of isolated CD45+ cells.

### Claim 15 (depends on 1)

A cellular therapy kit comprising the multi-component cellular therapy product of claim 1, wherein the kit further comprises written instructions for using the cellular therapy for treating a hematologic malignancy in a human subject.

### Claim 16 (depends on 1)

The multi-component cellular therapy product of claim 1, wherein the neutral pH ranges from approximately 6.8 to approximately 7.6.

### Claim 17 (depends on 1)

The multi-component cellular therapy product of claim 1, wherein the excipient comprises a transport buffer, wherein the transport buffer is selected from the group consisting of: phosphate-buffered saline (PBS), human serum, PlasmaLyte, and any combination thereof.

### Claim 18 (depends on 17)

The multi-component cellular therapy product of claim 17, wherein the transport buffer further comprises approximately 0.1% weight by volume to approximately 10% weight by volume of a human carrier protein, wherein the human carrier protein is selected from the group consisting of: human serum albumin (HSA), intravenous immune globulin (IVIG), AB serum, and any combination thereof.

### Claim 19 (depends on 1)

The multi-component cellular therapy product of claim 1, wherein any of the first single dose bag, the second single dose bad, and the third single dose bag is a polyvinyl chloride (PVC) transfer bag or an ethylene vinyl acetate (EVA) transfer bag.

### Claim 20 (depends on 1)

The multi-component cellular therapy product of claim 1, wherein the one or more cryoprotectants are selected from the group consisting of: sorbitol, dimethyl sulfoxide (DMSO), propylene glycol, glycerol, polyvinylpyrrolidone (PVP), and polyethylene glycol (PEG), serum, HSA, hetastarch, CRYOSTOR CS2, CRYOSTOR CS5, and CRYOSTOR CS10.

### Claim 21 (depends on 6)

The method of claim 6, wherein the administering comprises infusing into the human subject the first population of isolated CD45+ cells, the second population of isolated CD45+ cells, and the third population of isolated CD45+ cells.
